Tuesday, March 30, 2004ValueClick Completes Japan SaleWestlake Village-based ValueClick (www.valueclick.com) announced that it has completed the sale of ValueCLick Japan to livedoor Co, Lt.d for $24M in cash.
posted on Tuesday, March 30, 2004(Full story)
Jazz Inks RF Foundry CustomerNewport Beach-based Jazz Semiconductor (www.jazzsemi.com) has been selected by Magnolia Broadband as the foundry for the company's radio frequency (RF0 solutions for the cellular industry. Magnolia will use Jazz for its specialty silicon germanium (SiGe) BiCMOS manufacturing process technology.
posted on Tuesday, March 30, 2004(Full story)
Gluecode Announces Business Automation ServerLos Angeles-bsaed Gluecode Software has announced the shipment of the company's Gluecode Enterprise Server, an open source business automation server. The company's software suite provides business process management, security management, and an enterprise portal, and is based on open source software. Gluecode is focused on creating application infrastructure applications based on open source software. Gluecode is backed by Palomar and Rustic Canyon Ventures.
posted on Tuesday, March 30, 2004 (More)(Full story)
CMS Solutions Launches Windows Content ManagersCamarillo-based CMS Solutions has launched two products for the managemnet of personal digital media files. The company's Game Genie product allows users to manage Windows games through a structured database; the company's Digital Jukebox software allows for the management of MP3 music files. CMS is headed by Martin Shum, and is staffed by a number of ex-Aprisa employees.
posted on Tuesday, March 30, 2004 (More)(Full story)
Amgen Makes $1.3B AcquisitionThousand Oaks-based Amgen (www.amgen.com) has made a $1.3B stock acquisition of Tularik, a drug discovery company.
posted on Tuesday, March 30, 2004 (More)(Full story)
Kemia Raises $33.5MSan Diego-based Kemia announced that it has raised $33.5M in a Series B, led by JPMorgan Partners. New investors Novo A/S and Hamilton Apex also participated, as well as all of the company's prior investors. Ron Ferguson of JPMorgan has also joined the company's board. Kemia is developing small molecule medicines targeted at inflammation, cancer, HIV, diabetes and bone diseases.
posted on Tuesday, March 30, 2004 (More)(Full story)